logo
Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week ® 2025

Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week ® 2025

Business Wire23-04-2025

BUSINESS WIRE)-- Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), today announced it will present immunogenicity and biomarker analyses from its Phase 2 study, in participants with stage F2 and F3 fibrosis due to MASH. The results will be presented in a state-of-the-art lecture and poster at Digestive Disease Week (DDW) in San Diego, May 3-6, 2025. These findings further support the advancement of the efimosfermin clinical program to a Phase 3 pivotal study in 2025.
'Efimosfermin has demonstrated rapid and strong response across liver and cardiometabolic biomarkers, along with a favorable safety and tolerability profile. Its once-monthly dosing is expected to be a significant advantage for both prescribers and patients, providing confidence that efimosfermin could set a new standard in MASH treatment,' said Sophie Kornowski, CEO of Boston Pharmaceuticals. 'With our robust data, along with the commitment from our Board and a strong funding strategy, we aim to accelerate efimosfermin's development and begin enrolling patients in a Phase 3 study in F2 and F3 patients before the end of the year, followed by an F4 trial after planned discussions with regulators.'
The state-of-the-art oral presentation will showcase results from the Phase 2, randomized, placebo-controlled, 24-week treatment study in participants with biopsy-confirmed F2 and F3 MASH. The study showed significant improvements in histopathology, with 45.2% (p=0.038) of participants treated with efimosfermin 300mg achieving fibrosis improvement ≥1 stage without worsening of MASH compared to 20.6% in the placebo group, and MASH resolution without worsening of fibrosis in 67.7% of participants (p=0.002) versus 29.4% at 24 weeks. Efimosfermin also demonstrated extrahepatic benefits, including positive impacts on lipids and in participants with diabetes, clinically meaningful improvements in glycemic control. In this study, efimosfermin was generally well-tolerated, with low discontinuation rates due to adverse events, and an overall low incidence of gastrointestinal side effects and injection site reactions. Data to be presented will also highlight the favorable immunogenicity profile of efimosfermin.
Exploratory analyses of the phase 2 study of changes in biomarkers that identify at-risk MASH patients will be presented as a poster. These results strengthen the histopathology findings, demonstrating rapid and marked effects on biomarkers of steatosis, fibrosis, and liver injury, and supports the potential of efimosfermin as a once-monthly, disease-modifying therapeutic for the treatment of MASH.
'These analyses further support the Phase 2 study findings and provides the scientific community with the confidence to advance the development of efimosfermin as a potential therapy for patients with F2 and F3 fibrosis,' said Mazen Noureddin, M.D., M.H.Sc., lead investigator and Professor of Medicine at Houston Methodist Hospital, and Director of the Houston Research Institute. 'Based on these encouraging results, we expect to see continued progress as we evaluate findings across histology and non-invasive markers in patients with F2 and F3 MASH receiving efimosfermin treatment for up to 48 weeks.'
Details of Boston Pharmaceuticals' presentations are as follows:
Digestive Disease Week 2025
Oral Presentation Title:
Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24 Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Abstract Number:
723
Session:
State-of-the-Art Lecture: Update on MASLD Therapies Pipeline
Session Date, Time:
Monday, May 5, 2025, 10:00 a.m. – 11:30 a.m. PDT
Presentation Time:
11:05 a.m. – 11:20 a.m. PDT
Location:
6F
Presenter:
Matthew Bryant, PharmD, Vice President of Medical Affairs, Boston Pharmaceuticals
Expand
Poster Presentation Title:
Once-Monthly Efimosfermin Alfa Improves FAST and FIB-4 Composite Biomarker Scores for MASH Stage F2-F3 Fibrosis in a 24-Week Phase 2 Trial
Abstract Number:
Sa1504
Session:
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Session Date, Time:
Location:
Halls C-E
Presenter:
Rohit Loomba, M.D., MHSc, Professor of Medicine, Chief in the Division of Gastroenterology and Hepatology, and Director of MASLD Research Center at University of California, San Diego
Expand
About MASH
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a growing global epidemic fueled by the increasing prevalence of obesity and type 2 diabetes. It is estimated that MASH affects millions of people worldwide, including 17 million in the U.S., and is expected to increase by 63% by 2030. MASH is a progressive disease staged by the degree of fibrosis (scarring) in the liver and is closely associated with multiple cardiometabolic risk factors. Left untreated, MASH could lead to liver failure, liver cancer or death. In the U.S., MASH is now a leading cause of liver transplantation.
About efimosfermin alfa
Boston Pharmaceuticals' lead investigational agent, efimosfermin alfa (formerly BOS-580) is a once-monthly subcutaneous injectable of a long-acting variant of human fibroblast growth factor 21 (FGF21) that regulates various metabolic pathways to decrease liver fat and ameliorate liver inflammation and damage in patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The Phase 2 clinical development program of efimosfermin is continuing with an open-label extension in F2 and F3 MASH patients, providing an additional 24 weeks of treatment to assess long-term safety and efficacy up to 48 weeks. Boston Pharmaceuticals also plans to initiate a supplemental study in F4 MASH to further expand and enrich the data set for this patient population.
About Boston Pharmaceuticals
Boston Pharmaceuticals, a portfolio company of B-FLEXION, is a clinical-stage biopharmaceutical company that leverages an experienced and committed drug development team to advance a portfolio of highly differentiated therapies that may address important unmet medical needs in serious liver diseases, with MASH as the focus of its lead asset. The Company has significant expansion opportunities through its portfolio of promising drug development candidates that were acquired through partnerships with proven, innovative biotechnology and pharmaceutical companies. Boston Pharmaceuticals applies rigorous decision-making to advance programs to deliver differentiated medicines to patients in need of new options while creating value for all parties involved in the journey.
For more information, please visit www.bostonpharmaceuticals.com and follow us on LinkedIn.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. This communication, other than statements of historic fact, are forward-looking statements.
Boston Pharmaceutical's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful. Boston Pharmaceuticals does not undertake to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this presentation except as required by law.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AM Best Withdraws Credit Ratings of FCCI Commercial Insurance Company and FCCI Advantage Insurance Company
AM Best Withdraws Credit Ratings of FCCI Commercial Insurance Company and FCCI Advantage Insurance Company

Business Wire

time9 minutes ago

  • Business Wire

AM Best Withdraws Credit Ratings of FCCI Commercial Insurance Company and FCCI Advantage Insurance Company

OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best has withdrawn the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of 'a' (Excellent) of FCCI Commercial Insurance Company and FCCI Advantage Insurance Company as these companies no longer operate as insurance companies. At the time of the withdrawal, the outlooks of these Credit Ratings (ratings) were stable. Both companies are domiciled in Sarasota, FL. AM Best's procedure is for a final rating opinion to be produced in conjunction with a rating withdrawal. However, final ratings could not be determined on these companies due to the absence of insurance licenses and liabilities. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Ultra Cyclist Philipp Kaider Embarks on Race Across America with Support from Radiometer
Ultra Cyclist Philipp Kaider Embarks on Race Across America with Support from Radiometer

Business Wire

time9 minutes ago

  • Business Wire

Ultra Cyclist Philipp Kaider Embarks on Race Across America with Support from Radiometer

CARLSBAD, Calif.--(BUSINESS WIRE)--On June 10, 2025, Austrian ultra-endurance athlete Philipp Kaider will begin his most ambitious challenge yet: the Race Across America (RAAM). Spanning nearly 5,000 kilometers from the Pacific to the Atlantic, RAAM is widely regarded as one of the toughest endurance races in the world—demanding continuous cycling across extreme terrain, weather conditions, and time zones. To help monitor his hydration and recovery throughout the event, Kaider's team will use the ABL90 FLEX PLUS blood gas analyzer to measure critical values such as electrolytes—ensuring he remains in peak condition across each stage of the race. Share This marks Kaider's first attempt at the iconic race, a feat that tests not just physical strength, but also mental focus and strategic precision. Supported by a mobile crew and detailed performance planning, Kaider is determined to cross the finish line with speed and resilience. 'RAAM isn't just a race—it's a life experience,' said Kaider. 'It's about pushing past what you thought was possible and discovering a new level of endurance. I've trained for years to reach this starting line.' RAAM represents the ultimate test of human endurance, and Philipp's story reflects the passion and perseverance we admire at Radiometer. To help monitor his hydration and recovery throughout the event, Kaider's team will use the ABL90 FLEX PLUS blood gas analyzer to measure critical values such as electrolytes—ensuring he remains in peak condition across each stage of the race. About Radiometer Whatever comes next, we make sure life comes first. Radiometer develops, manufactures, and markets solutions for blood sampling, blood gas analysis, transcutaneous monitoring, immunoassay testing, and related IT management systems. Today, Radiometer's products and solutions are used in hospitals, clinics, and laboratories in over 130 countries, providing information on critical parameters in acute care diagnostics. Through connected solutions, expert knowledge, and trusted partnerships, we help health care professionals make diagnostic decisions to improve patient care. To learn more, visit or contact Radiometer America at 1 (800) 736 0600. About RAAM RAAM, first held in 1982, differs from stage-based races by running non-stop from start to finish. Riders have no designated rest periods, making strategic decisions about sleep, nutrition, and pacing crucial for success.

Monarch Launches to Empower Women's Health Physicians with a Bold New Model for Independent, Membership-Based Care
Monarch Launches to Empower Women's Health Physicians with a Bold New Model for Independent, Membership-Based Care

Business Wire

time10 minutes ago

  • Business Wire

Monarch Launches to Empower Women's Health Physicians with a Bold New Model for Independent, Membership-Based Care

NEW YORK--(BUSINESS WIRE)-- Monarch has officially launched to transform the future of women's healthcare by enabling physicians to establish and operate independent, membership-based practices. Founded by physicians and industry veterans, Monarch's approach supports a sustainable alternative to traditional systems that limit time, access, and quality of care, ensuring doctors retain complete ownership, clinical decision-making authority, and professional autonomy. Addressing Crisis-Level Burnout and Patient Dissatisfaction After assembling its first physician cohort, Monarch launches amid growing urgency and demand for a better way to practice medicine. Recent reports show that nearly half of U.S. physicians report experiencing symptoms of burnout, which particularly impacts women's healthcare where complex care requires longer consultations that current reimbursement models fail to adequately support. Women across the country also face increasing delays, dismissals, misdiagnosis, and fragmented care. These disparities underscore the need for a better healthcare model. Monarch helps remove the friction and bureaucracy that drives burnout and prevents physicians from delivering the care their patients deserve. By providing comprehensive operational infrastructure, dedicated launch support, and robust practice management tools, Monarch enables physicians to spend significantly more time delivering thoughtful, preventive care that reflects the full complexity of women's health rather than being overwhelmed by administrative burdens. 'Monarch was built to address a fundamental failure in healthcare: The system is broken, and it's women who are too often overlooked, underserved, and left behind,' said Anna Lohrfink, Co-Founder and Chief Product Officer of Monarch. 'Our mission is simple: Empower great doctors to deliver the care women deserve—personal, proactive, and focused on helping them thrive in every stage of life.' Built for Physician Independence and Patient-Centered Care Monarch-affiliated physicians retain full ownership of their practices and complete clinical decision-making power. Monarch minimizes administrative burden—from staffing to billing, marketing, and technology integration—enabling physicians to maintain smaller patient panels, offer extended appointments, provide greater care continuity, and generate more predictable revenue through the membership model. 'Monarch makes it possible to practice medicine the way it was always meant to be practiced—rooted in deep relationships, centered on the full spectrum of health, and driven by clinical excellence,' said Dr. Suzanne Gilberg, Chief Clinical Officer, Monarch. 'We're not opting out of the healthcare system—we're building what it should have been all along, for both patients and physicians.' Proven Leadership and Vision Monarch's founding team combines deep expertise in healthcare delivery, digital health, and practice operations, supported by distinguished clinical advisors specializing in women's health, concierge medicine, and healthcare innovation. This helps ensure the platform remains grounded in the real needs of both patients and providers. "This is about giving physicians their professional identity back," added Lohrfink. "When doctors are free to build meaningful relationships with patients—without the noise of administrative red tape—healthcare finally does what it's meant to do: help people live healthier, fuller lives." About Monarch Monarch is the premier partner for women's health physicians who want to leave behind a high-volume, insurance-driven care and build independent practices that deliver exceptional, personalized care for women at every stage of life. Monarch provides the operational support, technology, and investment physicians need—without taking away ownership or clinical autonomy. With Monarch's proven model, physicians reduce patient volume, deliver proactive, personalized care, and build stronger relationships with their patients. Physicians interested in learning more about Monarch can visit and follow Monarch on LinkedIn.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store